In final guidance, NICE recommends Viekirax (ombitasvir�paritaprevir�ritonavir) with or without Exviera (dasabuvir) in hepatitis C- Abbvie

In final guidance, NICE has recommended Viekirax (ombitasvir–paritaprevir–ritonavir) with or without Exviera (dasabuvir), from Abbvie, as a possible treatment for adults with genotypes 1 and 4 chronic hepatitis C.

For genotype 1 hepatitis C, Viekirax + Exviera treatment in patients with or without cirrhosis should be for between 12 and 24 weeks and only in previously untreated patients. For genotype 4 hepatitis C, Viekirax alone is recommended in previously untreated patients, with or without cirrhosis, and should last between 12 and 24 weeks.

Comment: Cost of the combination is £10,733.33 for 28 days course. Total costs over 12 weeks and 24 weeks are £32,200 and £64, 400 respectively. Cost of dasabuvir (if needed) is £933.33 per 28 day pack and £3,100 and £6,200 for 12 weeks and 24 weeks respectively.